Gene Company is a new drug development company focusing on advancing novel RNA nanoparticle technologies to treat diseases of unmet medical need.
Gene Company has entered into an exclusive licensing agreement with Griffith University to develop and commercialize a novel RNAi drug candidate as a universal treatment for COVID-19 and other viral respiratory infections caused by coronaviruses. Under the terms of the agreement, Griffith University will receive up to AUD$135 million in upfront and potential milestone payments and further royalties on global sales with a multi-billion-dollar market potential.
News
siRNA: Short for "small interfering RNA or silence RNA," siRNA is a class of double-stranded RNA molecules that play a vital role in regulating gene expression. siRNA is designed to target and silence specific genes, preventing them from producing harmful proteins or overproducing detrimental products through the RNA interfering (RNAi) pathway.
siRNA is a revolutionary tool with immense potential to transform medicine. Its ability to precisely target and silence specific genes has opened up a world of possibilities for treating a wide range of diseases, such as infectious diseases, cancers, and rare diseases. With ongoing research and development, siRNA-based therapies hold the promise of providing safer and more effective treatments for some of the traditionally challenging medical conditions. To date, there have been 4 siRNA-based drugs approved by FDA while only one of them being a siRNA-LNP (lipid nanoparticle) drug. We hope to explore this frontier further and develop siRNA-LNP drugs for medical conditions with unmet needs.
Science
Management Team
Gene Company is led by a management team with experience, background, and talents in building startup biotech companies into global billion-dollar public listed companies.
Yun-Ju Huang
Co-Founder and Managing Director
Miss Huang has extensive experience in private and investment banking, portfolio management and venture capital investment with a focus on early-stage investment in revolutionary technologies and taking startup companies to initial public offering (IPO).
Kevin V. Morris, PhD
CSO
Dr Kevin V. Morris is an American born Australian resident scientist and corresponding author on over 130 peer-reviewed publications. Research from the Morris laboratory was the first to uncover a role in human cells for non-coding RNAs in the control gene transcription and epigenetic states. More recently he has developed several RNAs drugs that control of key genes involved in human diseases and innovative methods to use lipid nanoparticle or extracellular vessicle nanoparticle delivery vehicles to modulate these genes and ameliorate disease. The power of controlling gene expression in a specific manner juxtaposed with innovative nanoparticle delivery technologies are the essence of Gene Company’s core technologies.
Gene Company Pty Ltd
info@gene-company.com
L11, 307 Queen St, Brisbane City QLD 4000, Australia